Emerging Pharmaceutical Market in China - Forecast to Become The Worlds Third-Largest Pharmaceutical Market By 2013 - GBI Research Reports

Emerging Pharmaceutical Market in China - Forecast to Become The Worlds Third-Largest Pharmaceutical Market By 2013

Emerging Pharmaceutical Market in China - Forecast to Become The Worlds Third-Largest Pharmaceutical Market By 2013 - GBI Research Reports
Emerging Pharmaceutical Market in China - Forecast to Become The Worlds Third-Largest Pharmaceutical Market By 2013
Published Sep 17, 2011
85 pages — Published Sep 17, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs new report, Emerging Pharmaceutical Market in China - Forecast to Become The Worlds Third-Largest Pharmaceutical Market By 2013, provides in-depth analysis of trends, issues and challenges in this industry. The report analyzes the effective strategies that shape the industry dynamics. Further, the report provides competitive benchmarking for the leading companies and analyzes the M&A and strategic partnerships that shape the Chinese pharmaceutical market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

Scope

The scope of this report includes -
- Overall pharma, biotech and outsourcing market structure.
- Market characterization, including market size
- CMO & CRO market size and growth
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies.
- Key M&A activities and strategic partnership deals that have taken place in 2009

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments poised for strong growth.
- Device a more tailored country strategy through the understanding of key drivers and barriers of the countrys pharmaceutical market.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

  
Source:
Document ID
GBIHC114MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents34
  List of Tables51
  List of Figures61
Emerging Pharmaceutical Market: China Introduction74
  GBI Research Report Guidance101
Emerging Pharmaceutical Market: China Macroeconomic Environment114
  Demographic Analysis112
  PEST Analysis131
    Political Factors131
    Economic Factors141
    Social Factors141
    Technological Factors141
Emerging Pharmaceutical Market: China Industry Performance1517
  China (Past, Present and Future Scenario)151
    Macroeconomic Indicators154
    Population Profile191
    Environmental Burden of Disease191
      Number of Major Infections in China191
      Number of Deaths Occurring by Diseases in China201
      HIV/AIDS211
      Cardiovascular Diseases (CVD)221
      Diabetes231
      Cancer241
      Chronic Obstructive Pulmonary Diseases (COPD)251
    Healthcare Spending and Financing261
    Imports and Exports272
    Branded and Generic Drugs291
    Healthcare Infrastructure291
      Key Players in the Hospital Section302
Emerging Pharmaceutical Market: China Pharma and Biotech Industry3222
  Pharmaceutical Market Size and Growth in China321
  Biotech Market Size and Growth in China331
  Major Regulatory Bodies in China341
    SFDA (State Food and Drug Administration)341
    CDE (Center for Drug Evaluation)341
    NDRC (National Development and Reform Commission)351
    NICPBP (National Institute for the Control of Pharmaceutical and Biological Products)351
  Key Pharmaceutical Regulations in China361
    Ministry of Health361
      Provincial Department of Health361
      City Department of Health361
      Township Department of Health361
      Village Health Administration361
    The National Development and Reform Commission371
    Chinese Center for Disease Control and Prevention (China CDC)371
    The Ministry of Finance371
    Ministry of Labor and Social Security (MoLSS)371
  Pricing and Reimbursement in China381
    Pricing of Pharmaceutical Drugs in China381
    Reimbursements of Pharmaceutical Drugs in China391
  Intellectual Property Rights in China391
    Patent Law401
    Trademark Law401
    Anti-Unfair Competition Law411
    Regulations on Customs Protection of Intellectual Property Rights421
  Key Marketing and Distribution Channels in China421
    Current Distribution Situation in China431
    Modern Pharmaceutical Logistics in China431
    Foreign-Invested Distributors in China431
  Key Distributors Foreign441
    AstraZeneca China441
    Bayer Schering Pharma China441
    Shanghai Roche Pharmaceutical Corp.441
    Xian-Janssen (Johnson &Johnson)441
    Sanofi-Aventis441
  Key Distributors Domestic451
    Sinopharm Group Co. Ltd.451
    Shanghai Pharmaceutical Co. Ltd.451
    Jointown Group Corp461
    Harbin Pharmaceutical Group Corp.461
    Taiji Group Corp.461
  M&A Deals471
    Top 10 Deals Summary Between 2009 and 2011471
      Shanghai Pharmaceutical to Acquire CITIC Pharmaceutical, announced January 2011471
      Shanghai Pharmaceutical Completes Acquisition Of 55% Stake in China Health System, in 2011471
      Shanghai Pharmaceutical to Acquire Stake in SIIC Medical Science, Mergen Biotech and In Shanghai Fudan-zhangjiang Bio-Pharmaceutical, announced the same in 2009471
      Sinopharm to Acquire 60% Stake in Shijiazhuang Lerentang, announced in 2011471
      Shenzhen Accord Pharmaceutical to Acquire 52% Stake in Sinopharm Holdings Shenzhen TCM, announced the same on 2010471
      Roche Holding Enters Into Co-Development Agreement with Aileron Therapeutics, in 2011481
      Sanofi-Aventis Extends Its Tender Offer to Acquire Genzyme, announced in 2010481
      Johnson &Johnson Acquires Crucell, in 2011481
      Roche Holding Acquires Marcadia Biotech, 2010481
      AstraZeneca Acquires Novexel, in 2010481
  Licensing Agreements491
    Top 10 Licensing Deals Summary Between 2009 and 2011491
      Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca, in 2009491
      AstraZeneca Enters Into Licensing Agreement with Rigel Pharmaceuticals, in 2010491
      PTC Therapeutics Enters Into Licensing Agreement with F. Hoffmann-La Roche, in 2009491
      Avila Therapeutics Enters into Licensing Agreement with Sanofi-Aventis, in 2010491
      Algeta Signs Licensing Agreement with Bayer, in 2009501
      Shanghai Institutes For Biological Sciences Enters Into Licensing Agreement with Sanofi-Aventis, in 2010501
      Prometheus Laboratories Signs Licensing Agreement with Bayer Schering Pharma, in 2010501
      Targacept Expands License Agreement with AstraZeneca, in 2009501
      Ascenta Therapeutics Enters Into Licensing Agreement with Sanofi-Aventis, in 2010501
      Digital Biotech Enters Into Licensing Agreement with Roche Holding, in 2010511
  Market Drivers and Restraints511
    Market Drivers521
      High Growth in Medical Equipment Market521
      Growth in Pharmaceutical Industry Sector521
      Booming Healthcare Construction Market521
      Opportunity in Hospital Information Systems Sector521
    Market Restraints521
      Regulatory and Bureaucratic issues521
      Weak Intellectual Property Protection521
      High Cost of Prescription Drugs531
      Financial Disparity and Coverage Problems531
      Inadequate Infrastructure and Qualified Workforce531
      Language Barrier531
Emerging Pharmaceutical Market: China Service Industries Contract Research and Manufacturing Services (CRAMS)5426
  Introduction541
  CMO Market Size and Growth in China541
    Key CMO Companies Domestic551
      Shanghai Pharmaceutical Group551
      Zhejiang Hisun Pharma551
      WuXi AppTech551
      Shandong Xinhua Pharmaceutical561
      Tianjin Pharmaceutical561
      Shandong Lukang Pharmaceutical561
    Key CMO Companies Foreign571
      Lonza571
      Boehringer Ingelheim581
      DSM591
      Evonik601
      Dalian Pfizer Pharmaceutical Co.611
  CMO Market Drivers and Restraints621
    CMO Market Drivers621
      Increased Utilization of Biologics for Disease Therapy621
      Increase in Number of Government Sanctions and Policies Favoring CMOs621
    CMO Market Restrains631
      Regulatory Approvals631
      Insufficient Communication Platform631
  CRO Market Size and Growth in China632
    Key CRO Companies Domestic651
      Wuxi Pharma Tech.651
      Shanghai ChemPartner Co. Ltd.661
      Shanghai Genomics, Inc.671
      Zensun (Shanghai) Sci &Tech Co., Ltd.681
      Shanghai LeadDiscovery Pharma691
    Key CRO Companies Foreign701
      Quintiles Transnational Corp701
      Covance711
      Pharmaceutical Product Development Inc. (PPD)721
      Charles River Laboratories731
      PAREXEL International741
    Top 10 Deals Summary Between 2009 to 2011751
      Royal DSM Acquires Martek Biosciences, in 2011751
      Boehringer Ingelheim Acquires Additional 33.6% Stake in SSP, in 2010751
      Pharmaceutical Product Acquires BioDuro, in 2009751
      Royal DSM Acquires Microbia from Ironwood Pharmaceuticals, in 2010751
      Charles River Laboratories Acquires Cerebricon, in 2009751
      Tianjin Chase Sun Pharmaceutical to Acquire Minority Stake in Tcmages Pharmaceutical, 2010751
      QPS and Quintiles Collaborates for Cardiac Safety Service761
      Covance and Eli Lilly Entered into a Strategic R&D Collaboration761
      Charles River Acquired Systems Pathology Company761
      Perceptive Informatics Enhances Musculoskeletal Medical Imaging Capabilities through Alliance with Optasia761
    Top 10 Licensing Summary Between 2009 to 2011761
      f-star Biotechnologische Enters Into Licensing Agreement With Boehringer Ingelheim, in 2010761
      Lpath Enters Into Licensing Agreement with Pfizer, in 2010761
      Cleveland BioLabs Enters Into Licensing Agreement with Zhejiang Hisun Pharmaceutical761
      Roswell Park Cancer Institute Enters Into Licensing Agreement with Zhejiang Hisun Pharmaceutical, in 2010771
      The Medicines Company Enters Into Licensing Agreement with Pfizer, in 2009771
      Covance Agreed to Provide Genomic Analysis Services to Merck &Co., Inc., in 2009771
      Seattle Genetics Enters Into Licensing Agreement with Pfizer, in 2011771
      Depomed Enters Into Licensing Agreement with Boehringer Ingelheim, in 2011771
      Biocon Enters Into Licensing Agreement with Pfizer, in 2010781
      Covance Enters Into an Agreement with Sanofi-Aventis, in 2010781
  CRO Market Drivers and Restrains781
    CRO Market Drivers791
      Increasing R&D Expenditure and Decreasing Productivity in the Biopharmaceutical Industry Promoting R&D Outsourcing791
      Availability of a Large Pool of Clinical Scientists791
      The Chinese Government Has Encouraged Foreign Investment791
    CRO Market Restraints791
      Intellectual Property Issues Are Not Fully Resolved791
      In-depth Training in GCP s for Health Care Professional791
Emerging Pharmaceutical Market: China Service Industries Healthcare IT801
  Healthcare IT Market Size and Growth in China801
Emerging Pharmaceutical Market: China Appendix815
  Market Definitions811
  Abbreviations811
  Research Methodology822
    Coverage821
    Secondary Research831
    Primary Research831
    Expert Panel Validation831
  Contact Us841
  Disclaimer841
  Sources842

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Emerging Pharmaceutical Market in China - Forecast to Become The Worlds Third-Largest Pharmaceutical Market By 2013" Sep 17, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Pharmaceutical-Market-in-China-Forecast-to-Become-The-Worlds-Third-Largest-Pharmaceutical-Market-By-2013-2115-259>
  
APA:
GBI Research Reports. (2011). Emerging Pharmaceutical Market in China - Forecast to Become The Worlds Third-Largest Pharmaceutical Market By 2013 Sep 17, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Pharmaceutical-Market-in-China-Forecast-to-Become-The-Worlds-Third-Largest-Pharmaceutical-Market-By-2013-2115-259>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.